Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD BMS-986442: Differentiated TIGIT & CD96 bispecific antibody in Oncology Antagonizes TIGIT & CD96 binding to CD155 MOA: Drives T & NK cell anti-tumor immunity Dual TIGIT & CD96 antagonist IL-2 [pg/mL] 400- 300- 200- 100- BMS-986442 Fc selected to enhance tumor- reactive T cell responses Program Overview: Licensed from Agenus Phase 1 single-agent trial complete Phase 1/2: Evaluating combinations (e.g., PD-1 ± chemotherapy) in dose escalation with data anticipated next year Positive data enables clinical development acceleration Initial tumors of interest: NSCLC & Gastric cancer CD96 & TIGIT are complementary targets in the same pathway & negatively regulate T & NK cell function in the tumor microenvironment 1,2,3 BMS-986442 potentially enhances the quality & magnitude of T cell responses (vs TIGIT & CD96 monospecific antibodies) through dual inhibition on APC or tumor cells4 IgG BMS-986442 anti-TIGIT anti-CD96 anti-TIGIT+ anti-CD96 APC: T-Cell Response (Bispecific vs monospecific(s)) T Ill Bristol Myers Squibb™ 1. Waight JD, et al., Cancer Cell. 2018. 2. Worboys JD, et al., Nat. Communi. 2023. 3. Banta KL, et al., Immunity 2023. 4. Dougall WC, et al., Immunol. Rev. 2017 Not for Product Promotional Use 102

View entire presentation